Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

نتائج البحث

Display Settings
النتائج لكل صفحة: 10
Sort By: Relevance
Filter
  • 1-10 ل  97 نتائج ل ""Cytochrome P-450 CYP3A Inhibitors""

فلترة النتائج

Subject : drug interactions
إعادة تعيين خيارات الفبترة
Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request
Academic Journal

An open-label study to explore the optimal design of CYP3A drug-drug interaction clinical trials in healthy Chinese people.

  • Authors : Chen J; Research Ward, Beijing Friendship Hospital, Capital Medical University, Beijing, China.; Li J

Subjects: Drug Interactions* ; Midazolam*/Midazolam*/Midazolam*/pharmacokinetics ; Midazolam*/Midazolam*/Midazolam*/administration & dosage

  • Source: Pharmacology research & perspectives [Pharmacol Res Perspect] 2024 Aug; Vol. 12 (4), pp. e1252.Publisher: John Wiley & Sons Ltd, British Pharmacological Society and American Society for Pharmacology and Experimental Therapeutics Country of Publication: United States

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي
×
Academic Journal

The effect of itraconazole, a strong CYP3A4 inhibitor, on the pharmacokinetics of the first-in-class ACKR3/CXCR7 antagonist, ACT-1004-1239.

  • Authors : Huynh C; Department of Clinical Pharmacology, Idorsia Pharmaceuticals Ltd, Allschwil, Switzerland.; Department of Pharmaceutical Sciences, Biopharmacy, University of Basel, Basel, Switzerland.

Subjects: Itraconazole*/Itraconazole*/Itraconazole*/pharmacokinetics ; Itraconazole*/Itraconazole*/Itraconazole*/administration & dosage ; Itraconazole*/Itraconazole*/Itraconazole*/pharmacology

  • Source: Clinical and translational science [Clin Transl Sci] 2024 Jul; Vol. 17 (7), pp. e13883.Publisher: WileyBlackwell Pub Country of Publication: United States NLM ID: 101474067 Publication Model: Print Cited Medium: Internet ISSN:

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي
×
Academic Journal

A physiologically-based pharmacokinetic precision dosing approach to manage dasatinib drug-drug interactions.

  • Authors : Kovar C; Clinical Pharmacy, Saarland University, Saarbrücken, Germany.; Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany.

Subjects: Dasatinib*/Dasatinib*/Dasatinib*/pharmacokinetics ; Dasatinib*/Dasatinib*/Dasatinib*/administration & dosage ; Dasatinib*/Dasatinib*/Dasatinib*/pharmacology

  • Source: CPT: pharmacometrics & systems pharmacology [CPT Pharmacometrics Syst Pharmacol] 2024 Jul; Vol. 13 (7), pp. 1144-1159. Date of Electronic Publication: 2024 May 01.Publisher: Wiley Country of Publication: United States NLM ID: 101580011 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي
×
Academic Journal

Tipifarnib physiologically-based pharmacokinetic modeling to assess drug-drug interaction, organ impairment, and biopharmaceutics in healthy subjects and cancer patients.

  • Authors : Okudaira N; Certara, UK Ltd. (Simcyp Division), Sheffield, UK.; Burt H

Subjects: Drug Interactions* ; Models, Biological* ; Neoplasms*/Neoplasms*/Neoplasms*/drug therapy

  • Source: CPT: pharmacometrics & systems pharmacology [CPT Pharmacometrics Syst Pharmacol] 2024 Aug; Vol. 13 (8), pp. 1366-1379. Date of Electronic Publication: 2024 May 28.Publisher: Wiley Country of Publication: United States NLM ID: 101580011 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي
×
Academic Journal

Effect of drug interactions with non-vitamin-K oral anticoagulants on thromboembolic events in patients with nonvalvular atrial fibrillation.

  • Authors : Chen JH; Biostatistics Center, College of Management, Taipei Medical University, Taipei, Taiwan.; Graduate Institute of Data Science, College of Management, Taipei Medical University, Taipei, Taiwan.

Subjects: Atrial Fibrillation*/Atrial Fibrillation*/Atrial Fibrillation*/drug therapy ; Atrial Fibrillation*/Atrial Fibrillation*/Atrial Fibrillation*/complications ; Drug Interactions*

  • Source: Annals of the Academy of Medicine, Singapore [Ann Acad Med Singap] 2024 Feb 28; Vol. 53 (2), pp. 69-79. Date of Electronic Publication: 2024 Feb 28.Publisher: Academy Of Medicine, Singapore Country of Publication: Singapore NLM ID: 7503289 Publication Model: Electronic Cited Medium: Internet

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي
×
Academic Journal

Model-based assessments of CYP3A-mediated drug-drug interaction risk of milademetan.

  • Authors : Hong Y; Quantitative Clinical Pharmacology, Daiichi Sankyo, Inc, Basking Ridge, New Jersey, USA.; Ishizuka T

Subjects: Drug Interactions*; Cytochrome P-450 CYP3A Inhibitors/Cytochrome P-450 CYP3A Inhibitors/Cytochrome P-450 CYP3A Inhibitors/*pharmacokinetics ; Indoles/Indoles/Indoles/*pharmacokinetics

  • Source: Clinical and translational science [Clin Transl Sci] 2021 Nov; Vol. 14 (6), pp. 2220-2230. Date of Electronic Publication: 2021 Jun 23.Publisher: WileyBlackwell Pub Country of Publication: United States NLM ID: 101474067 Publication Model: Print-Electronic Cited Medium: Internet

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي
×
Editorial & Opinion

CYP-associated drug-drug interactions: A mission accomplished?

  • Authors : Pelkonen O; Research Unit of Biomedicine, Pharmacology and Toxicology, University of Oulu, Aapistie 5 B (POB5000), N90014, Oulu, Finland. .; Hakkola J

Subjects: Cytochrome P-450 CYP3A* ; Cytochrome P-450 CYP3A Inducers* ; Cytochrome P-450 CYP3A Inhibitors*

  • Source: Archives of toxicology [Arch Toxicol] 2020 Nov; Vol. 94 (11), pp. 3931-3934. Date of Electronic Publication: 2020 Oct 06.Publisher: Springer-Verlag Country of Publication: Germany NLM ID: 0417615 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي
×
Academic Journal

Novel Bruton's Tyrosine Kinase inhibitor remibrutinib: Drug-drug interaction potential as a victim of CYP3A4 inhibitors based on clinical data and PBPK modeling.

  • Authors : Huth F; Novartis Institutes for BioMedical Research, Basel, Switzerland.; Schiller H

Subjects: Drug Interactions*; Cytochrome P-450 CYP3A Inhibitors/Cytochrome P-450 CYP3A Inhibitors/Cytochrome P-450 CYP3A Inhibitors/*metabolism ; Protein-Tyrosine Kinases/Protein-Tyrosine Kinases/Protein-Tyrosine Kinases/*antagonists & inhibitors

  • Source: Clinical and translational science [Clin Transl Sci] 2022 Jan; Vol. 15 (1), pp. 118-129. Date of Electronic Publication: 2021 Aug 25.Publisher: WileyBlackwell Pub Country of Publication: United States NLM ID: 101474067 Publication Model: Print-Electronic Cited Medium: Internet

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي
×
Academic Journal

Time- and NADPH-Dependent Inhibition on CYP3A by Gomisin A and the Pharmacokinetic Interactions between Gomisin A and Cyclophosphamide in Rats.

  • Authors : Zhai J; School of Traditional Chinese Materia, Shenyang Pharmaceutical University, Shenyang 110016, China. .; Department of Pharmacy, Changzheng Hospital, Second Military Medical University, Shanghai 200433, China. .

Subjects: Drug Interactions*; Cyclooctanes/Cyclooctanes/Cyclooctanes/*pharmacology ; Cyclophosphamide/Cyclophosphamide/Cyclophosphamide/*pharmacology

  • Source: Molecules (Basel, Switzerland) [Molecules] 2017 Aug 08; Vol. 22 (8). Date of Electronic Publication: 2017 Aug 08.Publisher: MDPI Country of Publication: Switzerland NLM ID: 100964009 Publication Model: Electronic Cited Medium: Internet ISSN: 1420-3049

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي
×
Academic Journal

Physiologically-based pharmacokinetic modeling to predict drug interactions of lemborexant with CYP3A inhibitors.

Subjects: Computer Simulation* ; Drug Interactions*; Cytochrome P-450 CYP3A Inhibitors/Cytochrome P-450 CYP3A Inhibitors/Cytochrome P-450 CYP3A Inhibitors/*pharmacokinetics

  • Source: CPT: pharmacometrics & systems pharmacology [CPT Pharmacometrics Syst Pharmacol] 2021 May; Vol. 10 (5), pp. 455-466. Date of Electronic Publication: 2021 May 01.Publisher: Wiley Country of Publication: United States NLM ID: 101580011 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي
×
  • 1-10 ل  97 نتائج ل ""Cytochrome P-450 CYP3A Inhibitors""